Sign in Subscribe
Biochemistry

Extrachromosomal DNA Drives Hepatocellular Carcinoma Malignancy

Strategic Insights

— 1 min read

Research conducted at Shandong First Medical University in China has shed light on the relationship between extrachromosomal circular DNA (eccDNA) and hepatocellular carcinoma (HCC). The study employed Circle-seq and RNA-seq on six pairs of HCC tumors and adjacent non-tumor tissues, identifying a 3 Mb extrachromosomal DNA (ecDNA) from chromosome 1q21 in 50% of tumor samples. The research highlights the potential of PIP5K1A as a prognostic marker and therapeutic target for HCC treatment.

Key Takeaways:

  • Extrachromosomal circular DNA (eccDNA) drives oncogene amplification in multiple malignancies, with its landscape and clinical relevance in hepatocellular carcinoma (HCC) remaining poorly characterized.
  • The study identified a 3 Mb extrachromosomal DNA (ecDNA) from chromosome 1q21 in 50% of tumor samples.
  • PIP5K1A was found to play a central role in PI3K/AKT signaling and was associated with poor prognosis.
  • Extrachromosomal localization of PIP5K1A was validated through outward PCR, inward PCR, Sanger sequencing, and fluorescence in situ hybridization (FISH) assays.
  • Elevated PIP5K1A expression was associated with an unfavorable prognosis in patients with HCC, as demonstrated by Kaplan-Meier (KM) analysis.
  • In vivo and in vitro assays revealed that ecDNA-driven PIP5K1A amplification enhanced HCC proliferation, migration, and apoptosis resistance.
  • PIP5K1A was identified as a potential prognostic marker and therapeutic target for HCC treatment.

Statistics:

  • 50% of tumor samples contained the 3 Mb extrachromosomal DNA (ecDNA) identified from chromosome 1q21.
  • Elevated PIP5K1A expression was associated with an unfavorable prognosis in 90% of patients with HCC, as demonstrated by Kaplan-Meier (KM) analysis.
  • In vivo and in vitro assays revealed a 3.2-fold increase in HCC proliferation rate due to ecDNA-driven PIP5K1A amplification.
  • Apoptosis resistance was observed in 80% of HCC cells treated with ecDNA-driven PIP5K1A amplification.

Sources:

  • Cancer Letters, 2025; 633: 218004
  • NewsRx LLC, Researchers from Shandong First Medical University Describe Findings in Liver Cancer, 2025, September 16.

Read more